[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345498-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345498-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","liss-enables-immune-evasion-of-colorectal-cancers-irrespective-of-msi-status-research-findings","LISS enables immune evasion of colorectal cancers irrespective of MSI status - Research findings","","Immune checkpoint blockade (ICB) benefits only a subset of colorectal cancer patients, with limited effectiveness in both microsatellite stable and microsatellite instability disease. The study identifies LISS, a new immunoregulatory long non-coding RNA, whose expression increases in colorectal cancer and correlates with poor prognosis and heightened CD8+ scoring. LISS disrupts T cell cytotoxicity by preventing CamKIIγ-dependent STAT1 serine 727 phosphorylation, thereby reducing STAT1 activation and downstream MHC-I expression. LISS modulation and its antisense oligonucleotide therapies restore MHC-I and improve ICB responses in vivo.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/liss-enables-immune-evasion-of-colorectal-cancers-irrespective-of-msi-status-research-findings/345498/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/liss-enables-immune-evasion-of-colorectal-cancers-irrespective-of-msi-status-research-findings/345498.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in colorectal cancer immunotherapy?","Question",{"text":63,"@type":64},"ICB shows limited and inconsistent outcomes in colorectal cancer, including both microsatellite stable (MSS) and microsatellite instability (MSI) cases. The work focuses on mechanisms that enable immune evasion beyond mutational burden.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is LISS and how is it related to colorectal cancer outcomes?",{"text":68,"@type":64},"LISS is identified as an immunoregulatory long non-coding RNA. Its expression is increased in colorectal cancers and associates with poor prognosis and a high CD8+ score.",{"name":70,"@type":61,"acceptedAnswer":71},"How does LISS impair immune responses at the molecular level?",{"text":72,"@type":64},"LISS directly interacts with the kinase regulatory domain in CamKIIγ via two independent RNA stem-loops. This blocks STAT1 serine 727 phosphorylation, reducing STAT1 activation and MHC-I gene expression, which undermines T cell-mediated cytotoxicity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345498,1790556502,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nLISS enables immune evasion of colorectal cancers irrespective of MSI status  \nQingyu Lin1,2, Xingwen Wang 1,3,4, Weixu Zhao 1, Shiying Song 1, Yi Zhang1, Jiangwen Ma 1, Tianyu Li1, Yuhan Wei 1, Minqiao Lu1, Guixue Hou 5, Meiqi Wang 1, Hao Liu1, Shanliang Zheng 1, Olga Burenina6, Zhiyuan Xiang 1, Li Li7, Jiaqi Zhu8 and Ying Hu 1,2,3,4 ✉  \n\n|  | Despite being hailed as a signiﬁcant advancement in cancer treatment, immune checkpoint blockade (ICB) has not yielded favorable outcomes in colorectal cancer, both in approximately 85% of cases characterized by microsatellite stability (MSS) and approximately 50% of microsatellite instability (MSI) cases. How ICB efﬁciency in colorectal cancer treatment can be improved remains unclear. Here, we identify a new immunoregulatory long non-coding RNA (lncRNA) gene named lncRNA of IFN-γ-signaling suppressor (LISS) . LISS expression is increased in colorectal cancers and is linked to poor prognosis, as well as a high CD8+ score. Functional studies reveal that LISS impairs T cell-mediated cytotoxicity, regardless of MSS/MSI status. Mechanistically, LISS interacts directly with the kinase regulatory domain in calmodulin-dependent kinase (CamK)IIγ through a microdomain containing two independent RNA stem-loops. This interaction prevents the binding and phosphorylation of its substrate signal transducer and activator of transcription1 (STAT1) at serine(S)727, a modiﬁcation necessary for optimal activation of STAT1 and the subsequent major histocompatibility complex I (MHC-I) gene expression. Analysis of human colorectal cancer samples reveals signiﬁcant inverse correlations between LISS and pS-STAT1 or MHC-I. The knock-in of LISS in intestinal epithelium promotes adenoma development in Apcmin/+ mice. LISS antisense oligonucleotide (ASO)-based therapies enhance the responses of both MSS and MSI colorectal cancers to ICB in vivo, mainly by restoring MHC-I expression. Therefore, we have identiﬁed the previously uncharacterized lncRNA LISS to bea regulator of T cell immunity. Targeting it may be an effective therapeutic strategy to improve ICB in colorectal cancers with |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| varying MSI characteristics. |  |  |\n|  | Signal Transduction and Targeted Therapy (2026)11:197 ; [https://doi.org/10.1038/s41392-026-02671-y](https://doi.org/10.1038/s41392-026-02671-y) |  |\n|  |  |  |\n\nINTRODUCTION  \nCancer immunotherapy success hinges on overcoming immune evasion, with immune checkpoint blockade (ICB) being a primary strategy. While effective in melanoma and non-small-cell lung cancer, ICB often fails in colorectal cancer.1,2 Approximately 85% of colorectal cancer cases are microsatellite stable (MSS) and highly resistant to ICB, partly due to low tumor mutational burden and limited neoantigens.3 However, ICB resistance is not conﬁned to MSS cases. Even in microsatellite instable (MSI) cases, which typically have a higher mutational burden, about 50% of patients still develop primary or secondary ICB resistance.4 This highlights that factors beyond the tumor’s mutational load also inﬂuence the response to ICB.  \nDisruptions in the interferon (IFN)-γ signaling pathway—often caused by mutations in IFNGR1/2, JAK1/2, or β2M—are frequently associated with clinical resistance to immune checkpoint blockade (ICB) .5 Effector T cells secrete IFN-γ, which activates the JAK/STAT pathway and induces IFN-stimulated genes (ISGs) to enhance antigen processing and immune recognition.6,7 While this explains the link between IFN-γ impairment and ICB resistance, such genetic dysfunction is only one contributing factor.8,9 The  \nmechanisms governing IFN-γ pathway activation remain incompletely und","cbCaidbTKy4VJMtR","https://ap.wps.com/l/cbCaidbTKy4VJMtR","pdf",12656435,14,"English","# Introduction\n## Immune checkpoint blockade in colorectal cancer\n## IFN-γ signaling and immune evasion\n## Long non-coding RNAs in antitumor immunity\n# Main findings\n## Identification of LISS and clinical associations\n## Mechanistic effects on T cell function\n## Impact on STAT1 activation and MHC-I expression\n## In vivo models and therapeutic implications","[{\"question\":\"What problem does the study address in colorectal cancer immunotherapy?\",\"answer\":\"ICB shows limited and inconsistent outcomes in colorectal cancer, including both microsatellite stable (MSS) and microsatellite instability (MSI) cases. The work focuses on mechanisms that enable immune evasion beyond mutational burden.\"},{\"question\":\"What is LISS and how is it related to colorectal cancer outcomes?\",\"answer\":\"LISS is identified as an immunoregulatory long non-coding RNA. Its expression is increased in colorectal cancers and associates with poor prognosis and a high CD8+ score.\"},{\"question\":\"How does LISS impair immune responses at the molecular level?\",\"answer\":\"LISS directly interacts with the kinase regulatory domain in CamKIIγ via two independent RNA stem-loops. This blocks STAT1 serine 727 phosphorylation, reducing STAT1 activation and MHC-I gene expression, which undermines T cell-mediated cytotoxicity.\"}]","LISS enables immune evasion of colorectal cancers irrespective of MSI status - Research findings | PDF",1790057888,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9b2a0a184fc29d50d67744d45827292.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0ffb1a3683e00efa2475f7c6f704fbd.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fe246ce1bbc8ed02b273c9470eaf9f4.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/563b6e998496879e029db4be62f7aac0.webp",980,1301]